Branched chain amino acids are associated with the heterogeneity of the area of lipid droplets in hepatocytes of patients with non‐alcoholic fatty liver disease

2019 ◽  
Vol 49 (8) ◽  
pp. 860-871 ◽  
Author(s):  
Eiji Kakazu ◽  
Akitoshi Sano ◽  
Tatsuki Morosawa ◽  
Jun Inoue ◽  
Masashi Ninomiya ◽  
...  
Keyword(s):  
Amino Acids ◽  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Lipid Droplets ◽  
Branched Chain Amino Acids ◽  
Alcoholic Fatty Liver ◽  
Branched Chain ◽  
Alcoholic Fatty Liver Disease

scholarly journals Non-Alcoholic Fatty Liver Disease and Risk of Incident Type 2 Diabetes: Role of Circulating Branched-Chain Amino Acids

Nutrients ◽  
2019 ◽  
Vol 11 (3) ◽  
pp. 705 ◽  
Author(s):  
Eline van den Berg ◽  
Jose Flores-Guerrero ◽  
Eke Gruppen ◽  
Martin de Borst ◽  
Justyna Wolak-Dinsmore ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Amino Acids ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Branched Chain Amino Acids ◽  
Elevated Plasma ◽  
Alcoholic Fatty Liver ◽  
Branched Chain ◽  
Alcoholic Fatty Liver Disease

Non-alcoholic fatty liver disease (NAFLD) is likely to be associated with elevated plasma branched-chain amino acids (BCAAs) and may precede the development of type 2 diabetes (T2D). We hypothesized that BCAAs may be involved in the pathogenesis of T2D attributable to NAFLD and determined the extent to which plasma BCAAs influence T2D development in NAFLD. We evaluated cross-sectional associations of NAFLD with fasting plasma BCAAs (nuclear magnetic resonance spectroscopy), and prospectively determined the extent to which the influence of NAFLD on incident T2D is attributable to BCAA elevations. In the current study, 5791 Prevention of REnal and Vascular ENd-stage Disease (PREVEND) cohort participants without T2D at baseline were included. Elevated fatty liver index (FLI) ≥60, an algorithm based on triglycerides, gamma-glutamyltransferase, body mass index (BMI) and waist circumference, was used as proxy of NAFLD. Elevated FLI ≥ 60 was present in 1671 (28.9%) participants. Cross-sectionally, BCAAs were positively associated with FLI ≥ 60 (β = 0.208, p < 0.001). During a median follow-up of 7.3 years, 276 participants developed T2D, of which 194 (70.2%) had an FLI ≥ 60 (log-rank test, p < 0.001). Cox regression analyses revealed that both FLI ≥60 (hazard ratio (HR) 3.46, 95% CI 2.45–4.87, p < 0.001) and higher BCAA levels (HR 1.19, 95% CI 1.03–1.37, p = 0.01) were positively associated with incident T2D. Mediation analysis showed that the association of FLI with incident T2D was in part attributable to elevated BCAAs (proportion mediated 19.6%). In conclusion, both elevated FLI and elevated plasma BCAA levels are associated with risk of incident T2D. The association of NAFLD with T2D development seems partly mediated by elevated BCAAs.

scholarly journals Lipid droplets associated perilipins protein insights into finding a therapeutic target approach to cure non-alcoholic fatty liver disease (NAFLD)

2022 ◽  
Vol 8 (1) ◽  
Author(s):  
Aman Sharma
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Therapeutic Target ◽  
Fatty Liver Disease ◽  
Lipid Droplets ◽  
Alcoholic Fatty Liver ◽  
The World ◽  
Associated Proteins ◽  
Pharmacological Target ◽  
Alcoholic Fatty Liver Disease

Abstract Background Non-alcoholic fatty liver disease (NAFLD) is now the most common form of chronic liver disease in the world, and it’s linked to a slew of other risk factors including diabetes, obesity, dysbiosis and inflammatory bowel disease. More than 30 years ago, a patient was diagnosed with fatty liver with excessive fat accumulation in hepatocytes, a disorder known as hepatosteatosis. There will be no promising therapeutic medicines available from 1980 to 2021 which can reverse the fatty liver to normal liver state. In this review, we highlighted on lipid droplet associated protein which play a major role in accumulation of fat in liver cells and how these cellular pathway could be a promising therapeutic approach to treat the fatty liver disease. Main body Over the last few decades, Western countries follow a high-fat diet and change their lifestyle pattern due to certain metabolic disorders prevalence rate is very high all over the world. NAFLD is a major health issue and burden globally nowadays. Researchers are trying to find out the potential therapeutic target to combat the disease. The exact pathophysiology of the disease is still unclear. In the present decades. There is no Food and Drug Administration approved drugs are available to reverse the chronic condition of the disease. Based on literature survey, lipid droplets and their associated protein like perilipins play an eminent role in body fat regulation. In this review, we explain all types of perilipins such as perilipin1-5 (PLIN1-5) and their role in the pathogenesis of fatty liver which will be helpful to find the novel pharmacological target to treat the fatty liver. Conclusion In this review, majorly focussed on how fat is get deposited into hepatocytes follow the cellular signalling involved during lipid droplet biogenesis and leads to NAFLD. However, up to date still there mechanism of action is unclear. In this review, we hypothesized that lipid droplets associated proteins like perilipins could be better pharmacological target to reverse the chronic stage of fatty liver disease and how these lipid droplets associated proteins hide a clue to maintain the normal lipid homeostasis in the human body.

Effect of specific amino acids on hepatic lipid metabolism in fructose-induced non-alcoholic fatty liver disease

2016 ◽  
Vol 35 (1) ◽  
pp. 175-182 ◽  
Author(s):  
Prasanthi Jegatheesan ◽  
Stéphanie Beutheu ◽  
Gabrielle Ventura ◽  
Gilles Sarfati ◽  
Esther Nubret ◽  
...  
Keyword(s):  
Amino Acids ◽  
Lipid Metabolism ◽  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Hepatic Lipid Metabolism ◽  
Alcoholic Fatty Liver ◽  
Hepatic Lipid ◽  
Alcoholic Fatty Liver Disease

Pancrelipase with branched-chain amino acids for preventing nonalcoholic fatty liver disease after pancreaticoduodenectomy

2015 ◽  
Vol 51 (1) ◽  
pp. 55-62 ◽  
Author(s):  
Shintaro Yamazaki ◽  
Tadatoshi Takayama ◽  
Tokio Higaki ◽  
Masamichi Moriguchi ◽  
Nao Yoshida ◽  
...  
Keyword(s):  
Amino Acids ◽  
Liver Disease ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Branched Chain Amino Acids ◽  
Nonalcoholic Fatty Liver ◽  
Branched Chain
Sign in / Sign up

Export Citation Format

Share Document